ProCE Banner Activity

Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial

Slideset Download
Conference Coverage
In this updated analysis of the patient cohort with newly diagnosed high-risk DLBCL, epcoritamab SC combined with R-CHOP had a manageable safety profile and yielded an ORR of 100% and a CMR of 77%.

Released: June 16, 2022

Expiration: June 15, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab